About CREON

CREON brings a legacy of leadership to the table

CREON® (pancrelipase) Delayed-Release Capsules is a pancrelipase which is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.1

CREON® (pancrelipase) Delayed-Release Capsules

Capsules shown are not actual size and do not represent the exact color shade. For illustrative purposes only. The active ingredient in CREON evaluated in clinical trials is lipase.

  • CREON was the first pancreatic enzyme replacement therapy (PERT) to receive FDA approval2
  • CREON is the #1 prescribed PERT3
  • CREON offers a wide range of dosing options to meet the lipase needs of your patients1
  • CREON was the first PERT with dosing for patients with EPI due to CP or pancreatectomy1,4
  • CREON was the first pancreatic enzyme approved by the FDA with coefficient of nitrogen absorption data for EPI in patients with cystic fibrosis2
  • Unrestricted access (no step edits) for 95% of patients and the lowest branded co-pay for 94% of patients5*

*Formulary Definitions: “Lowest branded co-pay” means the product is in the formulary tier status designated by the insurer as the lowest branded co-pay in the therapeutic class. “Unrestricted” implies no step edit, which can be different than requiring a prior authorization.

Learn how CREON® (pancrelipase) works

How does CREON work?

Learn More
CREON® (pancrelipase) is offered in different dosages, depending on a variety of factors

CREON offers a wide range of dosing strengths

See Dosing Strengths
Use the dosing calculator to help determine the proper dosage of CREON® (pancrelipase)

Determine an appropriate per-meal dose for your patients

Use Dosing Guide

Indications and Important
Safety Information

Indications1

CREON® (pancrelipase) Delayed-Release Capsules is a pancrelipase which is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

Important Safety Information

  • Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement in the treatment
    of cystic fibrosis patients. Exercise caution when doses of CREON exceed 2,500 lipase units/kg of body weight
    per meal (or greater than 10,000 lipase units/kg of body weight per day).
  • To avoid irritation of oral mucosa, care should be taken to ensure that CREON is not crushed, chewed, or retained in the mouth. CREON should always be taken with food.
  • Porcine-derived pancreatic enzyme products contain purines. Caution should be exercised when prescribing CREON to patients with gout, renal impairment, or hyperuricemia.
  • There is theoretical risk of viral transmission with all pancreatic enzyme products including CREON.
  • Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
  • Adverse reactions that occurred in at least 2 cystic fibrosis patients (greater than or equal to 4%) receiving CREON were vomiting, dizziness, and cough.
  • Adverse reactions that occurred in at least 1 chronic pancreatitis or pancreatectomy patient (greater than or equal to 4%) receiving CREON were hyperglycemia, hypoglycemia, abdominal pain, abnormal feces, flatulence, frequent bowel movements, and nasopharyngitis.
  • CREON is not interchangeable with any other pancrelipase product.

Reference: 1. CREON [package insert]. North Chicago, IL: AbbVie Inc.

  1. References:
  2. CREON [package insert]. North Chicago, IL: AbbVie Inc.
  3. US Food and Drug Administration. Department of Health and Human Services. NDA 20-725. April 30, 2009. http://www.accessdata.fda.gov​/drugsatfda_docs​/appletter​/2009​/020725s000ltr.pdf. Accessed August 11, 2015.
  4. IMS Health, IMS National Prescription Audit, December 2015.
  5. US Food and Drug Administration. Department of Health and Human Services. NDA 020725/S-003. April 30, 2010. http://www.accessdata.fda.gov​/drugsatfda_docs​/appletter​/2010​/020725s003ltr.pdf. Accessed August 11, 2015.
  6. BusinessOne Technologies, May 2015.

back to top #tbd